Objectives Because existing publication guidelines and checklists have limitations when
used to assess the quality of cost-effectiveness analysis, we developed a novel quality …

Despite the global COVID-19 pandemic, during the past 2 years, there have been numerous
advances in our understanding of arrhythmia mechanisms and diagnosis and in new …

Cardiac implantable electronic devices (CIED) are potentially life-saving treatments for
several cardiac conditions, but are not without risk. Despite dissemination of recommended …

Aims Infections resulting from cardiac implantable electronic device (CIED) implantation are
severely impacting on patients' and on health care systems. The use of TYRXTM absorbable …

BACKGROUND: Antimicrobial envelopes reduce the incidence of cardiac implantable
electronic device infections, but their cost restricts routine use in the United Kingdom. Risk …

Background SyncAV, a device-based cardiac resynchronization therapy (CRT) algorithm,
promotes electrical optimization by dynamically adjusting atrioventricular intervals. Objective …

Background Hematoma is a complication of cardiac implantable electronic device (CIED)
procedures and may lead to device infection. The TYRX antibacterial envelope reduced …

Background: Cardiac implantable electronic device (CIED) infection has a high mortality.
Previous investigations showed reduced postoperative infections using skin preparation …

Cardiac implantable electronic device (CIED) infections represent a complication associated
with high morbidity and mortality. Despite enormous efforts to prevent them, the rates of …

Aims Use of an absorbable antibacterial envelope during implantation prevents cardiac
implantable electronic device infections in patients with a moderate-to-high infection risk …